mRNA COVID-19 vaccine in adolescence between 12-18 years of age with chronic disease mRNA COVID-19 vaccine adolescence chronic disease reactogenicity immunogenicity
Conditions
Interventions
Chronic disease with immunocompromised status which the last blood sample will be obtained at 3 months after complete vaccination.,Chronic disease with immunocompromised status which the last blood sa
Chronic disease with immunocompromised status 3 mo,Chronic disease with immunocompromised status 6 mo,Chronic disease without immunocompromised status 3 mo,Chronic disease without immunocompromised st
Sponsors
Pediatric Infectious Disease Society of Thailand (PIDST)
National Vaccine Institute (NVI)
Eligibility
Sex/Gender
All
Age
12 Years to 18 Years
Inclusion criteria
Inclusion criteria: Adolescence between 12-18 years of age at the enrollment date No history of COVID-19 vaccination No history of COVID-19 infection
Exclusion criteria
Exclusion criteria: Acute fever with body temperature above 37.8 degree Celsius within 3 days History of drug anaphylaxis or vaccine ingredient allergy History of lived vaccine administration within 4 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Immunogenicity 1 months after complete vaccination Anti-S-RBD antibody level and ELISpot,Reactogenicity 14 days after vaccination Diary card | — |
Secondary
| Measure | Time frame |
|---|---|
| Persistent of immune response 6 months after complete vaccination Anti-S-RBD antibody level and ELISpot,Immunogenicity 6 months after complete vaccination Anti-S-RBD antibody level and ELISpot | — |
Countries
Thailand
Contacts
Public ContactNapaporn Chantasrisawad
Faculty of Medicine, Chulalongkorn University
Outcome results
None listed